RALEIGH, N.C., July 30, 2018 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI), a leading commercial based specialty pharmaceutical company focused on patients living with chronic pain has appointed Thomas B. Smith, MD, FAAFP, as Chief Medical Officer and member of the Company’s Executive Leadership Team. Dr. Smith brings nearly thirty years of medical experience and expertise in the field of pain management to BDSI. His extensive and wide-ranging roles include having been Chief Medical Officer at various leading pain companies, head of medical affairs at top tier pharma and CRO companies, as well as running his own private practice. Dr. Smith is a highly published scientific author and has delivered more than 150 presentations in his field of expertise.
“We are thrilled to have Tom join BDSI at this important time of significant growth for our organization,” said Herm Cukier, Chief Executive Officer of BioDelivery Sciences. “Dr. Smith’s depth of industry experience and intimate knowledge of the pain space, including strong relationships with KOLs and leading policy institutions, will be extremely valuable as we continue to build our medical programs in support of our products. His extensive expertise makes him uniquely suited to help us realize our near and long-term goals and we are confident that he will be a great addition to the BDSI management team.”
“I am very excited to join the BDSI team and bring my industry and pain management expertise to this already impressive organization. BDSI is quickly becoming a leader in this field and I look forward to contributing to its continued success,” stated Dr. Smith.
Dr. Smith earned a Doctor of Medicine degree from the Indiana University School of Medicine and a Bachelor of Science degree from Purdue University. He is a member of several medical societies and organizations including the American Medical Association and the American Academy of Family Physicians. Tom will be based out of the company’s headquarters in Raleigh, North Carolina.
About BioDelivery Sciences International, Inc.
BioDelivery Sciences International, Inc. (NASDAQ:BDSI) is a specialty pharmaceutical company with a focus in the areas of pain management and addiction medicine. BDSI is utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA®) technology and other drug delivery technologies to develop and commercialize, either on its own or in partnership with third parties, new applications of proven therapies aimed at addressing important unmet medical needs.
